3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
3
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
41
Recurrence
9
Neoplasms, Plasma Cell
5
Smoldering Multiple Myeloma
3
Waldenstrom Macroglobulinemia
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
carfilzomib
×
Clear all
NCT04263480
2026-05-12
CZAR-1
University of Ulm
Phase 2
Active not recruiting
99 enrolled